Ibrutinib-induced severe liver injury

Amara G Nandikolla, Olga Derman, Deborah Nautsch, Qiang Liu, Hatef Massoumi, Sangeetha Venugopal, Ira Braunschweig, Murali Janakiram

Research output: Contribution to journalArticlepeer-review

Abstract

Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B-cell receptor pathway, is an effective therapeutic agent for B-cell lymphomas. As these drugs are novel, long-term or rare adverse events are not yet known. We report the first case of ibrutinib-induced severe liver injury in a patient with relapsed/refractory CLL.

Original languageEnglish (US)
Pages (from-to)735-738
Number of pages4
JournalClinical Case Reports
Volume5
Issue number6
DOIs
StatePublished - Jun 2017
Externally publishedYes

PubMed: MeSH publication types

  • Case Reports

Fingerprint Dive into the research topics of 'Ibrutinib-induced severe liver injury'. Together they form a unique fingerprint.

Cite this